Are patients with rheumatologic diseases on chronic immunosuppressive therapy at lower risk of developing severe symptoms when infected with COVID-19?

Vakil-Gilani, Kiana; O’Rourke, Kenneth S.

doi:10.1007/s10067-020-05184-3

Cited by 6 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the particular case of COVID-19, as mentioned above, there is little data of real risk of infection in NMD patients. However, several cohorts of patients with autoimmune diseases such as psoriasis, rheumatoid arthritis, multiple sclerosis, or optic neuromyelitis show that treatment with immunosuppressants does not increase the risk of suffering from COVID-19 and neither present a more severe form of infection (25)(26)(27)(28).…”

Section: Treatmentmentioning

confidence: 99%

Neuromuscular Diseases Care in the Era of COVID-19

Recasens

Rubio

2020

Front. Neurol.

View full text Add to dashboard Cite

The COVID-19 pandemic has pushed health systems to their limit and forced readjustment of standards of care for different pathologies. Management of neuromuscular diseases becomes a challenge since most of them are chronic, disabling, progressive, and/or require immunosuppressive drugs. There are three main aspects of COVID-19 that affect neuromuscular diseases care. The first one relates to how SARS-CoV2 directly affects different neuromuscular pathologies. Respiratory weakness, as seen in myasthenia gravis, amyotrophic lateral sclerosis, and myopathies, and the use of immunomodulatory drugs (Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy) make this group of patients potentially more vulnerable. Secondly, safety measures also affect proper care, limiting care continuity, and physical rehabilitation (one of the essential aspects of myopathies treatment). Telemedicine can partially solve the problem allowing for a continuum of close care, avoiding unnecessary visits, and even guaranteeing the attention of professionals from tertiary care centers. However, one of the crucial steps in neuromuscular diseases is diagnosis, and in most scenarios, more than one face-to-face visit is needed. Lastly, the global COVID-19 situation will also have an economic impact on patients and their families. This situation is of particular concern given that neuromuscular diseases already present difficulties due to the scarcity of resources in terms of public healthcare and research.

show abstract

Section: Treatmentmentioning

confidence: 99%

Neuromuscular Diseases Care in the Era of COVID-19

Recasens

Rubio

2020

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…COVID-19 has rapidly propagated worldwide in the past 2 years, causing a global pandemic (see, e.g., (Novelli et al, 2021), for a recent review). This highly contagious disease causes respiratory symptoms that range from mild to severe, and is associated with a number of other serious health implications, including lung inflammation and damage, thrombosis, stroke, renal failure, neurological disorders, and others (Hanff et al, 2020;Schmulson et al, 2020;Troyer et al, 2020;Vakil-Gilani and O'Rourke, 2020;Harapan and Yoo, 2021;Ostergaard, 2021). This list continues to grow, and despite extensive research in the past year and a half, full understanding of COVID-19 mechanisms of action and health consequences has not yet been achieved.…”

Section: Introductionmentioning

confidence: 99%

Protein Posttranslational Signatures Identified in COVID-19 Patient Plasma

Vedula

Tang

Speicher

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly contagious virus of the coronavirus family that causes coronavirus disease-19 (COVID-19) in humans and a number of animal species. COVID-19 has rapidly propagated in the world in the past 2 years, causing a global pandemic. Here, we performed proteomic analysis of plasma samples from COVID-19 patients compared to healthy control donors in an exploratory study to gain insights into protein-level changes in the patients caused by SARS-CoV-2 infection and to identify potential proteomic and posttranslational signatures of this disease. Our results suggest a global change in protein processing and regulation that occurs in response to SARS-CoV-2, and the existence of a posttranslational COVID-19 signature that includes an elevation in threonine phosphorylation, a change in glycosylation, and a decrease in arginylation, an emerging posttranslational modification not previously implicated in infectious disease. This study provides a resource for COVID-19 researchers and, longer term, and will inform our understanding of this disease and its treatment.

show abstract

“…COVID-19 has rapidly propagated worldwide in the past 2 years, causing a global pandemic (see, e.g., 2 for a recent review). This highly contagious disease causes respiratory symptoms that range from mild to severe, and is associated with a number of other serious health implications, including lung inflammation and damage, thrombosis, stroke, renal failure, neurological disorders, and others [3][4][5][6][7][8] . This list continues to grow, and despite extensive research in the past year and a half, full understanding of COVID-19 mechanisms of action and health consequences has not yet been achieved.…”

Section: Introductionmentioning

confidence: 99%

Protein Posttranslational Signatures Identified in COVID-19 Patient Plasma

Vedula

Tang

Speicher

et al. 2021

Preprint

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly contagious virus of the coronavirus family that causes coronavirus disease-19 (COVID-19) in humans and a number of animal species. COVID-19 has rapidly propagated in the world in the past 2 years, causing a global pandemic. Here, we performed proteomic analysis of plasma samples from COVID-19 patients compared to healthy control donors in an exploratory study to gain insights into protein-level changes in the patients caused by SARS-CoV-2 infection and to identify potential proteomic and posttranslational signatures of this disease. Our results suggest a global change in protein processing and regulation that occurs in response to SARS-CoV-2, and the existence of a posttranslational COVID-19 signature that includes an elevation in threonine phosphorylation, a change in glycosylation, and a decrease in arginylation, an emerging posttranslational modification not previously implicated in infectious disease. This study provides a resource for COVID-19 researchers and, longer term, will inform our understanding of this disease and its treatment.Key PointsPlasma from COVID-19 patients exhibits prominent protein- and peptide-level changesProteins from COVID-19 patient plasma exhibit prominent changes in several key posttranslational modifications

show abstract

Are patients with rheumatologic diseases on chronic immunosuppressive therapy at lower risk of developing severe symptoms when infected with COVID-19?

Cited by 6 publications

References 12 publications

Neuromuscular Diseases Care in the Era of COVID-19

Neuromuscular Diseases Care in the Era of COVID-19

Protein Posttranslational Signatures Identified in COVID-19 Patient Plasma

Protein Posttranslational Signatures Identified in COVID-19 Patient Plasma

Contact Info

Product

Resources

About